NEW YORK – Selux Diagnostics announced Monday it has received an additional $9.6 million from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
This is the third funding tranche Selux has obtained from BARDA under the company's milestone-based contract, which is worth up to $45 million. Selux has received $30.4 million in funding so far, including $11.4 million last October.
The Boston-based firm said it will use these funds to advance the development of its Next Generation Phenotyping technology, a rapid antimicrobial susceptibility test, through clinical trials. The platform will allow clinicians to offer personalized antimicrobial therapies within 24 hours to speed cures and reduce patient deaths.
The test is based on a microplate-compatible bacterial surface area assay that tracks how pathogens respond to antibiotics by monitoring their shape and size as they attempt to evade death.